Prostate Complex
Prostate Complex, licence 80076029: inactive licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- SISU
- NPN or DIN-HM
- 80076029
- Status
- Inactive licence
- Licence date
- 9 March 2017
- Revision date
- Not provided
- Form
- Capsule, molle
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine B6: up to 10 mg a day according to the dosing instructions published by Health Canada (2 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 2 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Dose déclarée au-delà d'une limite
Zinc: up to 30 mg a day according to the dosing instructions published by Health Canada (2 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 15 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- À vérifier
Zinc: up to 30 mg a day according to the dosing instructions published by Health Canada, above the limite de sécurité from EFSAEuropean Food Safety Authority. for adults (25 mg a day). Le repère de l'EFSA porte sur l'apport total d'une journée, alimentation et compléments.
limite supérieure de sécurité (UL). EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Cucurbita pepo Source : Graine(s) | 40.0 mg | Not calculated |
| Arctostaphylos uva-ursi Source : Feuille Extract : Matériel brut sec Extraction ratio : 2:1 Dry plant equivalent : 10 mg | 5.0 mg | Not calculated |
| Serenoa repens Source : Fruit Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 1600 mg Potency : 85.0 % Fatty acids | 160.0 mg | Not calculated |
| Vitamine B6 Source : Chlorhydrate de pyridoxine | 5.0 mg | 10,000 µg |
| Zinc Source : Gluconate de zinc | 15.0 mg | 30,000 µg |
Non-medicinal ingredients
Eau, Cire d'abeille, Lécithine, Maltodextrine, Dioxyde de silicium, Glycérol, Caramel, Dioxyde de titane, Gélatine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes de sexe masculin | Not specified | 2.0 Capsule | 1.0 Tous les jours |
Uses authorised in Canada
Used in Herbal Medicine to help relieve the urologic symptoms (e.g. weak urine flow, incomplete voiding, frequent daytime and night time urination) associated with mild to moderate benign prostatic hyperplasia.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use to exclude a diagnosis of prostate cancer.
Source
Official Health Canada record, licence 80076029
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.